Minoxidil is one of two FDA-approved treatments for hair loss and the most widely used topical hair loss medication in the world. It comes in concentrations ranging from 2% to 10% and higher through compounding. Choosing the right concentration matters: more is not always better, and the evidence for different strengths varies by patient profile.
What Is Minoxidil and How Does It Work?
Minoxidil was originally developed as an oral antihypertensive drug in the 1970s. Patients taking it orally for high blood pressure began growing hair in unexpected places — a side effect that led directly to its development as a topical hair loss treatment. The FDA approved 2% topical minoxidil for men in 1988 and 5% in 1997. A 5% foam formulation was approved in 2004.
Low-dose oral minoxidil for hair loss has been gaining clinical traction since about 2019.
The exact mechanism of minoxidil's effect on hair is not fully understood. It is a potassium channel opener that dilates blood vessels, improving blood flow and nutrient delivery to the follicle. It also appears to extend the anagen (growth) phase of the hair cycle and shorten the telogen (resting) phase, allowing follicles to produce hair for longer periods before cycling out.
Importantly, minoxidil works through a different mechanism than finasteride. It does not affect
DHT. Instead, it works on the follicle environment. This is why minoxidil and finasteride are often paired.
Minoxidil does not affect DHT, instead it improves the follicle environment and extends the growth phase. It’s a growth-supporting treatment that often works best when paired with DHT reduction.
2% vs. 5% Minoxidil: What the Evidence Shows
A pivotal study comparing 2% and 5% in men enrolled 393 men with androgenetic alopecia over 48 weeks. Results showed that 5% minoxidil:
- ● Produced 45% more hair regrowth than 2%
- ● Showed statistically significant betterity on investigator global assessment
- ● Produced earlier onset of regrowth — significantly more visible at 8 weeks than the 2% group
For women, the 2% concentration was the standard for many years. The 5% concentration is now FDA-approved for women as well. A study of 5% minoxidil foam in women found significantly greater hair regrowth and density compared to the 2% solution.
5% minoxidil is more effective than 2% in both men and women. The 2% concentration is not ineffective, but if the goal is maximum effectiveness, 5% is the evidence-supported choice.
What About Higher Concentrations — 7% and 10%?
Concentrations above 5% are not FDA-approved but are available through compounding pharmacies. Compounded minoxidil solutions at 7%, 10%, and occasionally higher are prescribed by clinicians for patients who have plateaued on standard concentrations.
The evidence for concentrations above 5% is limited compared to the data for 2% and 5%.
Several smaller studies and case series suggest that higher concentrations produce additional benefit for some patients, particularly those who failed to respond to 5% minoxidil.
A practical consideration is the vehicle. Minoxidil solution contains propylene glycol, which delivers the drug effectively but causes scalp irritation in up to 7% of users. Many compounding formulations at higher concentrations use alternative bases (ethanol, transcutol, or liposomal systems) to improve tolerability. These delivery bases can affect how well the drug penetrates the scalp and how much reaches the follicle.
Higher concentrations may benefit patients who have not responded to 5%, but the evidence base is smalle\
. If a higher concentration is being considered, the delivery vehicle matters as much as the percentage.
Oral Minoxidil: A Different Calculation
Low-dose oral minoxidil for hair loss has grown significantly in clinical use since 2018. Doses used for hair loss are far lower than the doses used for hypertension — typically 0.625 mg to 2.5
mg daily for women and 2.5 mg to 5 mg for men, compared to 10–40 mg for blood pressure management.
A 2020 retrospective study on oral minoxidil found hair density improvement in 79% of patients after six months. Similarly, a 2022 meta-analysis of 17 studies found that oral minoxidil was associated with consistent hair regrowth in androgenetic alopecia and other hair loss types.
The main advantage of oral minoxidil is convenience and consistency. Many patients struggle with daily topical application. A daily pill is simple, convenient, and zero-mess.
The main considerations with oral minoxidil are side effects. Fluid retention, lowered blood pressure, and hypertrichosis (unwanted hair growth on the face or body) are the most common.
At low doses, these are typically mild and well-tolerated, but require monitoring.
Oral minoxidil at low doses is an effective and increasingly used option that bypasses the compliance challenges of topical application. It is not right for every patient and requires clinical evaluation before starting.
Minoxidil and Propylene Glycol
Standard minoxidil solutions use propylene glycol as the penetration enhancer, the ingredient that carries the drug through the skin to the follicle. Propylene glycol is effective but causes contact dermatitis in a meaningful percentage of users. Reactions typically present as scalp itching, redness, flaking, or burning.
When patients experience these reactions, they often attribute them to the minoxidil itself and stop treatment. In many cases, the minoxidil is not the problem; the propylene glycol is.
Switching to a propylene glycol-free formulation or minoxidil foam (which uses a different vehicle) often resolves the reaction without losing the therapeutic benefit.
Scalp irritation from minoxidil is often caused by the propylene glycol carrier, not the minoxidil itself. A formulation change, not treatment stopping treatment, is usually the right response.
What to Expect by Concentration
Minoxidil works for most people, but the degree of response varies with concentration:
2% topical: Slows loss in most users. Visible regrowth in a moderate percentage, particularly at the vertex.
5% topical: More effective than 2% in published trials. Results can appear as soon as 3 months in. The standard recommendation for most men and women seeking maximum topical effectiveness.
7–10% compounded: Some evidence of additional benefit, particularly in combination formulas.
Low-dose oral 0.625–5 mg: Comparable or better results to topical for many patients, with different side effect considerations.
Concentration affects outcome, but 5% is the ideal concentration. 7-10% may be used to increase the likelihood of response rate.
Combining Minoxidil With Other Treatments
Minoxidil is most effective as part of a combination protocol. Typically, a combination of minoxidil and a 5-alpha reductase inhibitor (finasteride or dutasteride) is used. This addresses both the hormonal driver and the follicle environment.
Topical tretinoin has been shown to enhance minoxidil penetration. A study from the 1990s found that minoxidil combined with 0.01% tretinoin produced better results than minoxidil alone in men with androgenetic alopecia. This effect is attributed to tretinoin’s ability to increase sulfotransferase enzymes in the skin that activate minoxidil.
Minoxidil plus finasteride or dutasteride is the gold standard combination. Adding tretinoin to the topical minoxidil formula may enhance absorption and improve outcomes.
The Bottom Line
Minoxidil is effective across concentrations, with 5% consistently outperforming 2% in clinical trials. Concentrations above 5% are available through compounding and may benefit patients who have not responded to standard doses. Low-dose oral minoxidil is a growing alternative that bypasses the challenges of topical application. When using topical minoxidil, the delivery vehicle matters. Propylene glycol-free formulations are available for patients with scalp sensitivity. Minoxidil is most effective when combined with DHT suppression and used consistently over the long term.